• drugs market
  • Thus, high prevalence of bacterial conjunctivitis in the country demands effective medications, thereby driving the growth of the bacterial conjunctivitis drugs market in the U.S.However, despite the increasing incidence of bacterial conjunctivitis, the overall bacterial conjunctivitis market in the U.S. is likely to witness negative growth due to the patent expirations of major blockbuster drugs such as Vigamox, Moxeza, Zymaxid, and Besivance in the next few years. (persistencemarketresearch.com)
  • among which fluoroquinolones dominate the bacterial conjunctivitis drugs market in the U.S. with a share of more than 70% in 2013. (persistencemarketresearch.com)
  • With the loss of patent exclusivity, generics would offer physicians a broad range of affordable medications to prescribe, thereby significantly reducing the overall size of the bacterial conjunctivitis drugs market in the U.S. Hence, the future market growth would be contingent on commercialization of novel drugs for new indications. (persistencemarketresearch.com)
  • The U.S. bacterial conjunctivitis drugs market displays intense competitive rivalry among existing players, as currently the market is highly fragmented comprising both large and small pharmaceutical companies. (persistencemarketresearch.com)